0001493152-22-001662.txt : 20220120 0001493152-22-001662.hdr.sgml : 20220120 20220120083032 ACCESSION NUMBER: 0001493152-22-001662 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220120 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220120 DATE AS OF CHANGE: 20220120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jupiter Wellness, Inc. CENTRAL INDEX KEY: 0001760903 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 832455880 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39569 FILM NUMBER: 22540749 BUSINESS ADDRESS: STREET 1: 1061 E. INDIANTOWN RD. STREET 2: STE. 110 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: 561-325-0482 MAIL ADDRESS: STREET 1: 1061 E. INDIANTOWN RD. STREET 2: STE. 110 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: CBD Brands, Inc. DATE OF NAME CHANGE: 20181206 8-K 1 form8-k.htm
0001760903 false 0001760903 2022-01-20 2022-01-20 0001760903 us-gaap:CommonStockMember 2022-01-20 2022-01-20 0001760903 JUPW:WarrantsEachExercisableForOneShareOfCommonStockAt8.50PerShareMember 2022-01-20 2022-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 20, 2022

 

JUPITER WELLNESS, INC.

(Exact name of registrant as specified in charter)

 

Delaware   001-39569   83-2455880
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

1061 E. Indiantown, Suite 110

Jupiter, FL 33477

(Address of principal executive offices) (Zip Code)

 

561-462-2700

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   JUPW  

The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

         
Warrants, each exercisable for one share of Common Stock at $8.50 per share   JUPWW  

The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On January 20, 2022, Jupiter Wellness, Inc. (the “Company”) issued a press release . A copy of the press releae is attached hereto as Exhibit 99.1 , and is incorporated herein by reference.

 

The information in this Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing of ours under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Form 8-K in such filing.

 

Cautionary Statements

 

This filing and attached exhibit include “forward-looking statements.” All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Actual results could vary significantly from those expressed or implied in such statements and are subject to a number of risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. The forward-looking statements involve risks and uncertainties that affect our operations and financial performance. We do not undertake any duty to update any forward-looking statement except as required by law.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits  
     
  99.1 Press Release dated January 20, 2022
     
  104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 20, 2022

 

  JUPITER WELLNESS, INC.
   
  By: /s/ Brian S. John
    Brian S. John
    Chief Executive Officer

 

3
 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Jupiter Wellness’ Merger Partner Next Frontier Pharmaceuticals, Inc. Enters Psychedelic Drug Development and API Market

 

Next Frontier Pharmaceuticals’ Subsidiary Benuvia Signs Agreement with Global Wellness’ Shanti Therapeutics

 

  ● Benuvia has begun focusing on Psilocybin, DMT, and MDMA.
     
  ● Benuvia’s 83,000 square foot synthetic compound manufacturing facility is permitted by the U.S. DEA for Schedule I to III controlled substances, and is FDA registered.

 

JUPITER, FL and ROUND ROCK, TX, January 20, 2022 — Jupiter Wellness, Inc. (Nasdaq: JUPW), today announces that its merger partner, Next Frontier Pharmaceuticals, Inc., through its wholly owned subsidiary, Benuvia Manufacturing, Inc., has entered into the global psychedelic drug development and Active Pharmaceutical Ingredient (API) market by signing an agreement with Global Wellness Strategies Inc.(CSE:GWS) and Shanti Therapeutics Pty Ltd for management of their novel psychedelic development program using MDMA.

 

Benuvia, based in Round Rock, Texas, is a leading drug developer and provider of cannabinoid and psychedelic APIs. Benuvia has a growing portfolio of drug products and intellectual property, and an 83,000 square foot synthetic compound manufacturing facility that is permitted by the U.S. DEA for Schedule I to III controlled substances, and is FDA registered. Benuvia also has a platform of drug master files and drug development libraries, manufacturing process technologies, and intellectual property, including patents, for the development and manufacture of organic and synthetic cannabinoids, and has a pending application for quota with the U.S. DEA to manufacture psychedelic APIs. With this launch, Benuvia has begun focusing on three primary psychedelic ingredients: Psilocybin, N,N-Dimethyl-5-Methoxy-Tryptamine, or DMT, and 3,4-Methylenedioxymethamphetamine, or MDMA.

 

“We are excited to announce our entry into the global psychedelic market and our partnership program with emerging providers of psychedelic-based drugs focused on mental illness and chronic pain indications,” said Shannon Soqui, Executive Chairman of Next Frontier Pharmaceuticals. “As pharmaceutical companies become more aware of the positive effects of cannabinoids and psychedelic compounds for therapeutic use, the demand for APIs is expected to grow. Our diversified portfolio of APIs and entry into the development of novel psychedelic compounds aims to increase Next Frontier Pharmaceuticals’ and Benuvia’s position as a leading drug developer and provider of APIs focused on cannabinoids and psychedelics.”

 

1

 

 

As part of its launch into the market, Benuvia has signed an agreement to provide life cycle management services to Shanti Therapeutics for their psychedelic development program which uses MDMA. Benuvia will develop and file intellectual property on formulations of MDMA, and will provide full toxicology, and chemistry, manufacturing and controls, or CMC, and full data analysis. In addition, Benuvia, through its partners, will manage all research and development, manufacturing, analytical methods, intellectual property capture, placebo manufacture, randomization, and assistance with clinical trials. This will enable Benuvia to create custom technologies that allow rapid and cost-effective scale up of commercial operations for production in anticipation of research success.

 

“We are excited to partner with Shanti Therapeutics as we have a shared vision to develop and commercialize innovative medicines that provide an alternative treatment option for health care providers and their patients,” said Brandon Kidd, Chief Business Development Officer of Next Frontier Pharmaceuticals. “As pharmaceutical companies look to optimize the life cycle management of their cannabinoid and psychedelic drug products, Benuvia is an ideal partner to facilitate all facets of the process from drug development and formulation to manufacturing.”

 

“Shanti chose Benuvia as its development partner due to its proven track record and best in class status as a developer and manufacturer of synthetic APIs. We are creating a pipeline of novel agonists as a new class of therapeutics designed to treat the root causes of mental illness disorders and chronic pain.” said Meris Kott, CEO, Global Wellness Strategies Inc. “By partnering with Benuvia, Shanti will continue with its strategy of collaborating with the emerging leaders in the field to realize our mission to provide innovative new medicines to patients.”

 

About Jupiter Wellness

 

Jupiter Wellness, Inc. (Nasdaq: JUPW) is a leading developer of pharmaceutical cannabinoids focused on skincare therapeutics and treatments. The Company’s product pipeline incorporates cannabidiol (CBD) to address indications including psoriasis, eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenue from a growing line of proprietary over-the-counter skincare products and other wellness brands. For additional information, please visit www.jupiterwellness.com.

 

About Next Frontier Pharmaceuticals, Inc.

 

Next Frontier Pharmaceuticals, Inc., through its wholly owned subsidiary, Benuvia Manufacturing, Inc., is a leading drug developer and provider of cannabinoid and psychedelic APIs. Benuvia owns the FDA approved cannabinoid drug SYNDROS® (dronabinol oral solution CII), and the largest captive synthetic cannabinoid manufacturing facility in the U.S. SYNDROS® is FDA approved as a prescription drug for the treatment of chemotherapy-induced nausea and vomiting in cancer patients and loss of appetite in AIDS patients who have lost weight. Next Frontier Pharmaceuticals is also pursuing a 505(b)(2) approval pathway with the FDA for six Investigational New Drugs (INDs). The Company’s 83,000 square foot manufacturing facility in Texas is permitted by the U.S. DEA to manufacture and export Schedule I to III controlled substances and is FDA registered. The facility has received millions in manufacturing infrastructure investments and currently operates for Benuvia’s internal capacity needs and as a contract manufacturer of APIs. Next Frontier Pharmaceuticals also has a robust portfolio of patents and patents pending on organic and synthetic cannabinoids and provides life cycle management services for drug development companies focused on cannabinoids and psychedelics.

 

About Shanti Therapeutics Pty Ltd

 

Shanti Therapeutics Pty Ltd, a subsidiary of Global Wellness Strategies Inc. (CSE:GWS) (OTCQB: GWSFF) (Frankfurt:O3X4), is a clinical stage drug development company focused on identifying novel uses for MDMA in the treatment of acute and chronic pain management. Its core strategy involves identifying innovative uses for entheogen drugs and pushing them into in-human clinical trials. Its lead asset is scheduled to commence Phase 2 clinical trials in late 2022.

 

2

 

 

Jupiter Wellness Investor Contact:

Phone: 561-244-7100
Email: info@JupiterWellness.com

 

Next Frontier Pharmaceuticals Investor Contact:

Erik Fordyce, Head of Investor Relations

Email: efordyce@benuvia.com

 

Forward Looking Statements

 

This communication contains forward-looking statements regarding Jupiter Wellness, including, but not limited to, statements related to the proposed acquisition of Next Frontier Pharmaceuticals and the anticipated timing, results and benefits thereof, including the potential for Jupiter Wellness to accelerate its growth and cannabinoid leadership, and for the acquisition to provide long-term growth opportunities to create shareholder value; and other statements that are not historical facts. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the companies’ current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties, many of which are beyond Jupiter Wellness’ control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: Jupiter Wellness’ and Next Frontier Pharmaceuticals’ ability to complete the acquisition on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary regulatory and shareholder approvals, and satisfaction of other closing conditions to consummate the acquisition; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the proposed transaction; risks related to diverting the attention of management from ongoing business operations; failure to realize the expected benefits of the acquisition; significant transaction costs and/or unknown or inestimable liabilities; the risk of shareholder litigation in connection with the proposed transaction, including resulting expense or delay; the risk that Next Frontier Pharmaceuticals’ business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including the uncertainty of expected future regulatory filings, financial performance and results of the combined company following completion of the acquisition; Next Frontier Pharmaceuticals’ dependence on the successful commercialization of SYNDROS and the uncertain market potential of SYNDROS; pharmaceutical product development and the uncertainty of clinical success; the regulatory approval process, including the risks that the combined company may be unable to submit anticipated regulatory filings on the timeframe anticipated, or at all, or that the combined company may be unable to obtain regulatory approvals of any of its product candidates, and SYNDROS for additional indications, in a timely manner or at all; disruption from the proposed acquisition, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; effects relating to the announcement of the acquisition or any further announcements or the consummation of the acquisition on the market price of Jupiter Wellness’ common stock; the possibility that, if Jupiter Wellness does not achieve the perceived benefits of the acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Jupiter Wellness’ common stock could decline; potential litigation associated with the possible acquisition; regulatory initiatives and changes in tax laws; market volatility; and other risks and uncertainties affecting Jupiter Wellness and Next Frontier Pharmaceuticals and, including those described from time to time under the caption “Risk Factors” and elsewhere in Jupiter Wellness’ Securities and Exchange Commission (SEC) filings and reports, including Jupiter Wellness’ Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and future filings and reports by Jupiter Wellness. In addition, the extent of the impact on the combined company’s ability to generate sales of and revenues from its approved products, execute on new product launches, its clinical development and regulatory efforts, its corporate development objectives, and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time. Moreover, other risks and uncertainties of which the combined company is not currently aware may also affect each of the companies’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events at such dates, even if they are subsequently made available by Jupiter Wellness on its website or otherwise. Jupiter Wellness undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

 

3

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 jupw-20211228.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 jupw-20211228_def.xml XBRL DEFINITION FILE EX-101.LAB 6 jupw-20211228_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Warrants, each exercisable for one share of Common Stock at $8.50 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 7 jupw-20211228_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 20, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 20, 2022
Entity File Number 001-39569
Entity Registrant Name JUPITER WELLNESS, INC.
Entity Central Index Key 0001760903
Entity Tax Identification Number 83-2455880
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1061 E. Indiantown
Entity Address, Address Line Two Suite 110
Entity Address, City or Town Jupiter
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33477
City Area Code 561
Local Phone Number 462-2700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Entity Information, Former Legal or Registered Name Not Applicable
Common Stock [Member]  
Title of 12(b) Security Common Stock
Trading Symbol JUPW
Security Exchange Name NASDAQ
Warrants, each exercisable for one share of Common Stock at $8.50 per share  
Title of 12(b) Security Warrants, each exercisable for one share of Common Stock at $8.50 per share
Trading Symbol JUPWW
Security Exchange Name NASDAQ
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001760903 2022-01-20 2022-01-20 0001760903 us-gaap:CommonStockMember 2022-01-20 2022-01-20 0001760903 JUPW:WarrantsEachExercisableForOneShareOfCommonStockAt8.50PerShareMember 2022-01-20 2022-01-20 iso4217:USD shares iso4217:USD shares 0001760903 false 8-K 2022-01-20 JUPITER WELLNESS, INC. DE 001-39569 83-2455880 1061 E. Indiantown Suite 110 Jupiter FL 33477 561 462-2700 Not Applicable false false false false Common Stock JUPW NASDAQ Warrants, each exercisable for one share of Common Stock at $8.50 per share JUPWW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 3 122 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://jupiterwellness.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm jupw-20211228.xsd jupw-20211228_def.xml jupw-20211228_lab.xml jupw-20211228_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "jupw-20211228_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "jupw-20211228_lab.xml" ] }, "presentationLink": { "local": [ "jupw-20211228_pre.xml" ] }, "schema": { "local": [ "jupw-20211228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 1, "memberStandard": 1, "nsprefix": "JUPW", "nsuri": "http://jupiterwellness.com/20211228", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-01-20to2022-01-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://jupiterwellness.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-01-20to2022-01-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "JUPW_WarrantsEachExercisableForOneShareOfCommonStockAt8.50PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each exercisable for one share of Common Stock at $8.50 per share" } } }, "localname": "WarrantsEachExercisableForOneShareOfCommonStockAt8.50PerShareMember", "nsuri": "http://jupiterwellness.com/20211228", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001493152-22-001662-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-001662-xbrl.zip M4$L#!!0 ( ,]#-%2LX3[/N18 *9M * 97@Y.2TQ+FAT;>U=^U,; MQ[+^757Z'^9PZKKL*DD&'.<< Z$.SX03@PF0ZY.?;HUV1]*$?7EG%Z'\]??K MGIE]2$(XN7YP,4DEH-7N3$]/]]>/Z5YV?KHZ?;O;[>S\=+1WB)^"_MFY.KEZ M>[2[\]+^Q+-SO<:_8>RQ*SM/DN&)MO>>4D#8O7G?YGN0MT6?1GI<;(E M%%]\*3O[NT>W$SW41;?SYLU@8^?E_NXG6-C_UPWY"+K;N_9[:0H]FGW2+3DY M_5%<7AS\L*9NW[SI;_S/^OK&X/=LO";VWE[]L+;VA?:GO>?>JU M;(NA#*['>5HF83](HS3?$M.)+A2KU[_+#+_FW)@4!SG&%K3U8G,8QFHLM"!C##U21(,Q!$1;L2YF043%:I(!^(P M+\?B4-VH*,UB+$S()!1[YR?B5.;7JOAR^OSY]6*_DIFOLZ8O*SBR'!H=:IG/Q+Y*RALMQ26(-6)OG"O% C'5Q43\&*5#&8EY&;R<2 POKB8J MEQF/;<1C8>\]$G.UM__V2!P;YW<'+VXP]KZVO\^7SO\-!__M/+GNJP MF-"MZ_^%_4WS4.6TMY',#.CROZVQ"[5S=?'G)[A1.8N 9QL8O.8GUP=76"[C]_R;E^\^_7L$/\_^!GC_J@ ;(%H92%T(41 ML0T ,QL ]L1JC]_.@.$F6,QXPB-,)Y#"@-RS1&)"MQD0;7&%;=2@P+()TJ19FA>C--(I3<$48,ZP M#*#(;&F@DK!#4%;2PYP(*V;61X?JN$W\"^:QVZGLHX6>3V4D[["/%?@ M%+' M@BR26'H>=SM^Z;&DV\5(1\HN?P%L(CW,9:YIHK:Y!V\"@HM"!9,$S!_KBICE M+-1)$)6\[QGP)2G(OM-":>7S\%9/I6B;TGPL$["6OFHPNI8/-[-;IDIX&IEE M$!59Z#1ACL*_*:3%O":WNQWPMSGAO)P-Q'O[#+@<29B/20WMRT,\6 >%<7(= MD]EJCJVL?Y7/L@*JFBAP"VNH L97 MO>_XIEFD8'8T[J5G99R!-_9^<.T)1A_F8E; Z+,H)#_\O>IV"%O4;: )(2"B MWG<1:9F3YP#)6N$W>--/LD(/./_&3'16F5I6!44.D%-HAEY#&M<8J<]X;OT0 M8\44@PP&7ZH=0] M<72K@I+=F8.)U/!G$J)@928>Z.X8M0<<;3M!A+] "T6*B=^5B%,P4DZEQ1)B M5Y8:S1.JT4@1\K>MC5DP-Q[3C7"(Y;V>;@?(>M"#%S;O1(XXN6->+':(RYW6VB(VY;]*,J\B T.C8T'= V5]BXU7ST M&6B:="X0=$S"-LD_8;-Y"4Y& %C)2K::@1>+1Z'5#P.B_*Q_Z_?%L591"#L# M5WP;0W\H%? #%&R+=QGKY1:1< D9I7WN]WT*X_#DOSW-7XWQYT)^KE$_F*D7*>ZEB2PVAR*U(B?J+(S MBZ<>K>EP;X.%GGG;XFJ68?Z]'$(=;(LS&2O+X+.4&+C1?.BE?XJ^J;,4/D.Q M\Q)\7L+R(13WNC]40!*,G?'F-07B>U[Z>7N'W&F^E\#S]NA-HHA8N]=/BO8 M%K/"%]@#GI/=)F"E1(-U/FN[8$U\VQFE.%^%[3 ?MSN,ACL_4B*8!9%JANA& MY3>:LR+ILLB^\M,1Q-\7OH-TD CX-];YK(B;PD_P3[ AH*!C>:P@K,,>EY'U M'FC]-!A<8'J01_(+&I7X4*2WFE@W=I$:*(P1"%$.IAVT\))Q0(D 6Z*9T7#[3\#$,&0C6#&Y2OUT.[0EWJWJ6:HL3Q%S18C%C)(Y>,%A M5H82MJ 6]RS)3&^@]I">:0U6 A M'"A:9R^(=,(S%;DF-PK;##>%25#6&QRG0J M("4N/@]24_2M1P4/I]LQF$B),F/O*HWA9P:85-!BW+Z26+GHFPP0?$:2O4!G M-FC#W&+^4C3C%,>*Y;)L(K!LJ@!I\-*E,'!;\=R--B07 M>+P))+5L@20($?QCR=Y]C, X0"CLY-5!!H$(9!?V/K&W%23GUKG.JF3!1.$6 M* R174=&-)W#03S+28Q69+//.IB(GW48]A#.:#42^Y06H "I61_T;C0"X.:< MB5D=Z8B/"'2B-+TFKA#],3&!K,-RJ*^RL0W'W,)J"]F;>;':P%#V#FH:*D(E MMX&8UF6V""P(^?!1V9B*8RV7)QKE )&EN>P&U,_E8H"//D1X%)KRC:F]5>MN M)YBDIK8L4&RRG"WGPA=[[X#&P\8^S//5UH>XVSEPSC )<./[2'D24KG(A#SC1UQ9BTW8C%$ M:)9+5?:T2AM18H 6H1.^/J(H@_@ -C >4_()SI@';N^W-6":^%I!-2. !]?Y'%+E15+SV GSOTJV": MTLQS'DTS6=C(-)MKG; GUD)==L:\[T8I8?B/XH"=HEF=Q;1.3 WN&"G-,\(S M+-5-&.HT$L\/]@]?<*(]#'/"U4;^NGEX!=36$F%53ZC@#Q4#38=EGN C:,L( MP,#M4. N?QY&U--,\/<&5$E'TEVM5T$D2C%+> M!P^PH24EK&K&M,XP4V)3MS/U!F)(7BE,WC'\6A_0DB5*R/-RT6(6<;:8/.Q" M3*?3P>^64#_( -[FTTG2@UO,ZLH:A\,?T=3PC90:/0AH_B*+_5)E3!];T,&1 M[GT5'76V$%08]B>IK$%F' V$K>=YKLO?S@XOWET^R]5X6SP/L5K^.A+ ]X@. M(TH.Z ].3EXP%L.[I,@8^T1A!.73R %=6E)P9W5C4E/ IZRV=OC8*;3CVN+/2YJY"&_(Z*F(H!8]H M56F2 *ATY+R'.>)A>G.)**NTU&CF4>QW$RY$F>?X1.J8.3>!^#E_1$MIXCQA MQRD#!9@_49W.XW2H3P= KS:Q]6NC,=JLOO=U]Y0 M]O;>HITF0)A[CB;L&<1"_JC.@37G G7;)>#HOK18LY!9/']W=?#+_I; A^-C?#Q&B'0]*O-BZ]VK_WSG M:L;9M_%'9MT.[,!8W05!LR8 <\2XA(AHNX&!9+,Z'[\4UL3Y6Q M\Y.2"K 6#@I/Z/P9;AX=*2KH(7ACG.'D=!\?PM Y(ZP(XLC-^1%HS1&=$% ! M_U<]Q=L6\[7"CP^4EZSQ(^J"-I]*@#Y!"=#F4PG0MZQZGWA-"RE6%U!1[0IN MATN_]=7>%? 9? $O'QN'FYN;_USA&YQ/TD1M=3NOO]_H;W[W7?\?4%C/@\]$ M#>T']1BVQK^3P*-8ZFBK-G2?E+2U74K>_LL)Q_M&CO9A&9U'I]V?>8VKLW:+ MJO_5N7&'^'].-AWE^AH\@L,P"U1/_$1.*?SGBC<7RI4-?G.,8<3I=LAK(-[\ M:VC315\9%AXC#'RI6!]2/I5YV.V\3=-K"M4NJ^U1 M*/RV)4J4<*=SY93R%3+X4&K7ZG-?-:(O@*SK=&E$3$@$Y,J4DN>1TDD;4V'0CHU)MUV?K M3;[:4NA<,>^QPS!!G/:@;+L9B-_2DNAUY_UTP.8S-2NVO-MQQQ>EX1J ^3MI M 9J+L6=4&#VA9+^K^JHWIJI,==\,5:35S<)E7_VU>+V,0G^Q:K>CHYQXR>"V MTVW)52C XLW$SR6#T'%&$LY?C>5L@8R83J_F;\PB:.?\-2]G"U]0&^XBQ9"3 MWY?.V6B=@*J7TF'O]O2?2IM MG- M'0]3IC4----%SVW=R19Z]./:/(?N#02WG'>E$N]X#J)ZCO6[8 M8OXPT*>6+_5FU/=O._8VF,F=Q86WL;)P:LK5Q_61*LL^[&!*-PY]=T+=E@.? M!H$$G4O79;R6C*J?N3+O;D4M1C:4O[4^Z@]B:7@)+I;)=9).&>IH?D(;PKI( M6QF%E-@=H35R_78M *0]OJ" ZR'2)'$MK%4%PC*&M223%9A^HS4EAG_1#D5\X2P #N ME K]6=:\MU9K+^-U)09N^(:NCK!YR9A?[0&A3[CA"X+%A8:D*32W1^W:++4F M!U746&:5ET&JH3HM0?NXK0D5%25P#MXA6+T9K=ZA2D==64]E5JKE^Y>I6HI3YUDE=SD MQVZN*8$WT#E-FDT7]1:OW2"&PJMC2(:$FHQJ4C>AH:9O,QLVY'S!QK MT9 T\E38#0"_VKKI; H36$$ /(32D'O"[\'2'. Y2 =5B%2,:\;DQDIN'E60 M\W2F* *ALJF2WER#+[:K%U0T+((SPO9E((V>KK81SYF'=*(]X4J\^G8C*JUW MQG"Y?O'K&^HV8WJ=3<#1R-W>61Q3L7:1!M?;_CT;1@_KMQYA1Q8?%V$*4"+( MA*]*$8I]%%K)553 UKN-#?&:&U =JEKF !9L;UDMVD,2:0](ML/7,D*[M*'I M_9FUVC#>+]:[F8K4&'%B#0\-0S7GS37X$\W!6D,IV$W@N,%W"9$78IMMY"T, MH9R:;4\T7&_<2LQNAJIW>I>V47=)5N%^?Y+N:" 0.0?D28=';RH ,T:(#*'+0R]:X*])"%-ON G" V/86RW+S8@9*<'*V,XWRC:4 S@ MHMM"CO)<0T?[33F-<-:;74[D.-<^]'I#&V"'J56ZY]]70+X#OX_ \KTQ02/U M,]'C"7:W]A-\ELKZ@2[7X#4?N#O2H0TRV&)JPSHR$*:FU MU19-ZQI2^^XC,L)W>/5 LJ5.<"[6T%8TZ M:6NY&9(8$WB:C3.^TOJGXBFV8H5D]OQ7U$KX"PH=>-5E/;[\IX3UR!L$?NRC+<$2]@>X M44 -#968^UAXBFAWL&A%&/$+>4L(0LN,>>5]'>54?%5.U :CCB-M MH>LQF+3:F5J%L%U,M:P6T>[."Z*ERLO+T MXHI/]Z:$_R7]G37[ MA]?H[[/]+U!+ P04 " #/0S14K_>16^T5 IH0 "P &9O>YSSR ZRZ' /(B@NX(#+C%\\3=) -)M)1\!? M_U9U$@C;C$N< <>9<83T4DM75U=55W?V_C?45/+(+%LQ]*^19"P1(4R7#%G1 M>U\C#N]&\Y'_E38W]OH)P8;U4(I&,?S\[;4M]IM&HHMNLM%$*IK:"702M9DTU1%\C_6,QU_VDX^F MDWX_5 MN]3NB(I>@>@WFD@&L(82RU"9O;"-*%G02.96E(],9B]&"XKC6(PM$]@R-6XI M&8[.K=%BRKU" =!O8%M\'C5XN "KX\OSZW'=.\=4.+,&3%5U9MLQR=!$DV0J ME8^(&W"4QZ^1BJ%SIO/H!= 5(9+[ M[6N$LR&/NQ,[CNWB7K=[_XI&24UAJEPD;<9W28-JK$B&\G"7U _$A]M$JGQ[ MV?Y/ZN"P7#Z'7X@>B4:?VSI=O46*;Q=0>NM3^H+N,BEL!6*=2DP^/)T_:,<[ M@T;O/)]]05_9]"T#,0::X%]5!ZZ.*L NBZIU76;#$S:Z38"JR^TD"HGT2_HM M!/HM:TR7X8?75-J[[5+59B_H:F']PF[SU-)#;)SQZ21^IVW:?6LR^3=T* MA>MV8HMG+^GG '$Y]_I*SZ&TM/..(8^(S4#OB1W'@QY"Q54S3(T%!PQX1/B$)]B!&($BI=98 TPVZV!&KYH MBZ4;4"-B/2[VA?*&.3J(^I,R-K3EB%>,:O)KQ%8T4V6N"O% 37?N@K,-Q_*A M034A%46/&421?\H,7]7YS9@8A_'3\7-%QI*NPBPB2&$+U\5*_61ZS&8;3\#% M%\+SH)G 7T.>QP*,$XL?4,Y*$Q+\GB9E<\U@*)0<4V!^YA^XI*;;O9%:25AXH=*?E5YFC>BR_L/HA:?#%N?Y?02([-87,C1UBB&P MZ%,HBXZNN!()IL6@4$:I MJO2@2(()A:KKO_].[B1V]^)FZ3< &X,)V.1=XA5V# [:W2]/QK*3&DA9U%:>P"%( MFGS" 62Y]W\ O?@4?A]N0&R3ZC,0\K_V9?8ZI1,Y@ ML_53&,)&%80!]$BKVKC8W&A5SYNMBT\NOPN7SQW+=L#_V-S@!CR6<". )-/$ ML$@RNR5_(4:7\#[#(L=2N +=58=2G^JP9)8&,+C% M3,/B9 L?(,,9!7N7V9RP1X! +%',Y"]%,JLZ#V94Y[EPJ*JNN[58AWZ[&[0O M#J54IIQ\M0X-!BEE='^A75^FHQ%@SO1%.G8*,?",J>Y0:P2+[3;!CI=JWC48 MQE61N.NJZ>GC6J[O4WJC4ILW1?HK>J02J"*D7R[=AAE0Q5I:8- M3JG_R8VL[''K-7M-(NS Y5?CED[])^QU?';>%J;F;5V7# M6";'/+R*2%7=? MNF+(2Z;QT^/5&6-RAG;S8:P#F(Z P4'.3,MX1 &?7@B>@2>LB$RE UA"GC// MN1S"0(4\3C/S(!04?X,L[4_)4DU1&3"^PZS%@E-@Y>YEO=:Z.F6AZ?\)3 S> M)Z/I0G:G\"D%OU4*#J:DX((.Z]Z>B21FZ\]$XBY]DS[0GM(WUW)H(K$$ 7#4 MT]%4)IO-YQ//%!#XS_HCJT&8EH-0EBXNX+H9X+)9Y X\-EM6A$^WU[&\K7B" MEH425+1?0I+%59TC8?(9M^(4&[?X/(0"?$4M15PQ_&3I\UE:;[5=3*J:J1HC M9@5Y.CW'2<.(?5D\=^/"G"R%: *OOA(Z=C--UTF1_-[$ON+B!%K<-,Z!P<'UM6.F9_(5M .$'*USG"\SM0G5^X M<&*7+4:72ZV9/V&/^2O]?/CB^)*KVMXJZ$$4(Z7L3G)>L"<2W2E%9TG->Z2> M&A)5S_N&_E./_*BVLR^/?M1K5Z\/Z4]PGX49*65V4M%4+O'S16N5I7=K$E_^ M[[_SJ61N%V8H9RHSD4RB"SJWT6E2'0Q,$@IC!ZS[G)V_PW#8F0EEC@\LU> # MLTY9CZI-RQU"9C%Y^=:$>9R__*$:]+"5#6VU>AX^D5+#X)L;91,3--%16?N5 MS"76WZNP1*R7682Z"QQ,EBYQMXG!NT1KA*C4]OU!:?4:H:5H&&!>X6]PQAJ3#5&. XX&%.&PD'STA745%3:;8H-8XTV48 M)V[ 4&F.RJG.#,=61\0&N;:[(]'2:V!T &'7&?=2 P*[5 [T S)!]9%?V#54 M@(X-,>ZO8.#$)EM31 HVR$SRHE%%MQ<\I!@IV8SY)NLATYD%QE)=!V".FZA0 MCJ5B+GU?BNLQ3A]I*VP73Q%ST&>JSQUNF&'LCZ4RYC!FMA2BAX!1RF3W'37% MZ@SL/&(?=Q!F]4;:TQMM0QRT 'Q]YCM*8 MQV<--<:$"!ZRJ(TSS!\.6EG3M-]7=2S':PU5"! 3E0+4/,_Z2&;D M:&JK\^5Y"L6M^ZE25@VQCSL(RT[$S$S=NFT[S/JE8CEI[%]_3^@'HUXX&=[/ M5"QSV/T]ZB7-HIDMZ7GJQ:O[V[(<_MZ0V<3+W-RPQM':J>$;'X@1JX,7TH(A M^PPVK6RP:>:(67)5=F0D^NO,!+N<;9>(Q*?2+A_1 ?(7GU'48@F0]_ M!"PJCSW-]DCK&.J6_>63_PN)R(0_ W!7;'H",']-!(4[Z"OP)*"5PTS:?5]C M[ZVLF;'UJG[$R5VM1LE41RB/A;:=?UD35%]V[X9)Z>GE>><=!:R MLI+#OC5+7H6:"J>J1V P[^-CK^*KNBQ\XO51\?JP4VE9.F#X!G$(5S'>/OW8 MK^4[E]7F_=E+TD3>Y^K,G]K@/)]+LJ9YMTI2OL K^'0+5L@^ M_+UN03CZO/]8?;C1N#[,_7E)__0\PO<\/K?4PL,5C^1*XB*"SHA(F)*.4._) MH,_$C00SZ>**30 *S&)$K$=ZEC'@?=Q.-3&#G-I$9EU%=R\\\#')@))MZ7A$<5W$W95">:>N;M=GZO[@[MI&&@ MW]AZ#- Z"5/5DXO-C1G!F%U%_B^91E2@/SP24 M5Q_T$U.9Q$$_Z89(%W!L)FH!NMZ)&GS!EB)2"-R[[(57A;#4D9#L@0*P4:9U MP!>*+/:HV- 0U![5)D5^)2^3?93RJ!WEPAA:<]S M]"A_M,- G@(TI>.DQ0@B?RX6Q. 0&.?@N@*G> M@Y*U/D*U$MC5P2/?W,C%$DG28CU'I6(]JAV0 \665 /?]A%;2=S?UX")A--E MN'904]_9MX%^&0:^_-B]NDKDLQLH6F!%Z-D$KL>I:K^);<_0).G.V M)4+!*($&8,' 8@YV4(R407^8XX/ @5(F'#_.*=A7\N8&.(8,S!>*OE=?Z2B< M% JQ)-D&NTAVSR?[=]4!&*P,WB 89^.WR4V[7A]=F,*5 A$U4297&*"G+?Q: MG,I$S&3?T_5/C@?OP9@:,']$B3N@VSAV'8;5NHZE*S86X9#:?:JJPF3N,/#P MP1*7?=GJ*BJ3/UWBWNN"VT=W&]#EFNA=%"_P[Z(>(68<'^1E'FQN<#<#= MNTA:"A !\V]JD)$JVY'Z'EF?T8WP+VR@#@HRJ-_-C7$LVUX/W->)SQ<@UJ!* MW-F)ZF>LIIBGO%QU-M8+,$T&X&1'5<.X][QN;W!BGIH@99A>D\?>;:N\+]"; M/.T2 ,T-"\UATJ42MX4:05@RSOA%ZYI&1^A# \G M=^Y X:)ZH-XU2.)>>L6^=RLYH#PL3A4=]1O@I (@I]FZ6@Y@&5)A1I# M6(*8*6 #!08,8R9"T8%B!,9;# ,B%_. -S<"D!7]T5"AV1**78"TVT4F@=XG MALDL#RA6GH1QX+E89-%> >N*R(98 <4RP>D]$VN([/"1B".9L@BBBW5E&5L" M"M_"%WI;[L*DTL&::.O?XLZ$CK+KXQ30,JJ-1[<]/74\L\A^5V?G\ZC0GTQG M&A.1B&45_?7;EG)8-T6/T:.)%LVZ3E!5UD84O.OSV+KNS9J<^)\]$G M3C*1^;,(5,#NMURP(IY?1X4-[AAZ#P>44_>]#5N88B6C:X9[LIY/4M?Q&D+R M?;]U"A:[^ZJZ-7W_P,]WG5*[I&D*OZ6(_7I1MEUR154'B_^V3:F?&'S>;F> MF3X;=PF^*K9(RA;M*-(NP;P[E]4- QF8FMI;\EN)3=7/#:\5\1#??K"Y73]L ME"\N6]6U0?H/A/.\AXJ.KWHT,C MT1]U>-^P0%/):Q*H6:=P+[X_MCB_L[D>R'^D(,RJF;M $#[^&DF]YIT/KUX- MQF^J13QFWU8;WI46G]P..VH4QCW666$I_G'7;7*1T>O1V1\5?XK+>UPZDWL] MNGM**6['72SW+06Z:,?(L=''5X5]V$GW-^$ RS&U;LSYG-P/Q(.E;["NMX[ M(<>OQFJ*5V-9Y".&7]*!\,LIOB?E,]SR]G!+^K7AEF4!$1C#>,>01RAE\3[7 MU-+TJ+89][$8RL-=4C\0'VX3^?U;<23$??N)Z$VT8\?#Y'VUY@SNRM]:E_'R MT>5-2QTH;5[M)9I#8_^A9]3*UP^YHYOC8_NRET_(_6_-VO'CM229O?LKZ[IS M8I_'XX7.0-YO9.]&K>/+^_SY84*S#P\?++/:SE64GM%*M+2,TOV>/1X<)ZQ_ MU(O#BF99UE"^&]G9@Z>[8;_QQ5CS+:P9,T2->9 MO&\4;JY2AG[:NKHNGSX<'76@,*W?7!UPZO8[? M=S)WE9/,S?7Y/V?7H\93I6->'NH[24G7RD9W1^EH/RK#[V>5'5-2-8U?[:2M M[&E68]]D\[MVI/C_:! M5%>5FZYV=9@\/JH,3GX49*M0>QP-G$&EV;:^U;[9M4JNK)W5$[)3KUP?M#)- MVCQT,I?G/,[9>;QQE#'M1/R?3O>L\D_Y*&E<7V=[7[^Z0_3_4$L#!!0 ( M ,]#-%3?6R)DV@, $@. 1 :G5P=RTR,#(Q,3(R."YXROWY'L@T$" &: M\B1KOF]N&HV&UKMIRLD]*,VD:'M1+?0(B%@F3(S:WFW//^F==CH>>??VC]\) M_EI_^CZY8,"3)CF3L=\10_F&_$U3:)(/($!1(]4;\H7RW.[("\9!D5.99AP, MH*"PU"2'M2BBQ/>WT/L%1"+5[4UGIG=L3*:;03"93&I"WM.)5'>Z%LMT.X4] M0TVN9]K":5C^MJ-WF8YGY,91-].OIS?LZPC$<7Y&Q43W*7M_-+AN_'?X[_$5 MW(WO^^_#05_\=?#0E:QS'IZ<,M7M?:R/_@E/"I,M'8\AI00/0^BV9^,KPYL< MU*0:!?4PC(*OWPWD%L#GE3-RM@T>-1B-PT@JZ@IP.%*]4'P16/* :9II1 MRC;@F="&BO@1/C$SPB+X,"B$CZ!L+?2H@+(*FL 23D-<&\G[ 6(KT<_7E70 M7/LC2K,9?$CUP*DM!0[NAY%_$%44K2RA$:VB)44NT1YE$ M<6#%EAE:9GW&_'1[W9^1ON<9,Z FP+D [0K=&8OJ]6.\KAQ2$.9"JO0,AC3G M&-6/G'(V9)!XQ% U F,K5V "B'QLN"-+7?L7I8QO VX\5O+EDU3 M20Z?,0QB%WA--YJPF.!48L?Q"$O:7K&TRE"U4Y? D GF;);7,B*^O82Y#1.7 MCM(*EL$+*G(-R95XZ]:9 HT\%\0E;I3$$O($*:8\SOENG+DK:RGE1I6L>?JJ MJW<#0^*N;-/61-O3S#9-K]P;*QBV/R1XB9 Y'>P:,E* _\)8 M+ZW^%PT2*VG7(!\7WR^*]&QF9#'>8[IOO5>)Q#(7 M1CVX"+'2L?/)+,]*VQU*Q2H.Q(Y//U$O?1UYIC3*2T MP!?>KYAA@107/WE?$0W-$7Y-*!;>@"^6%"NLOX@;OO#.3[I=Y+7;%>K]BEG MQ9>[X;;>N5)+>='IK%:K$\:?T(J+1WGB\T6U"L<*J5!N:SM=GR;_XN+O*6&/ M%^;'!$GL:;V8O%A+J>GW<[OGV[&_APO4)LPHYN/6VDI M4XNM7/?=NW>=Z-L4NH=<3P1-VSCKI'2V->MO [4MD 6?=^(OLU!24'6&M"07 M,HKDAOM(13VDE)$'(LQO[136-H?:W5[[K'NRED$K]2D26W"*[_#4,_]KH[>M M_B]<$H7%"E/*L(PL[AA,9\!U%]:$H])S@:>7+8U=Z49ZW6ZO]]8T\6,.I#9+ MW94E,3VQY75RS2/AIPQLX&PK0+"IYB;*\ZCQN:Y"^.$$MP.RP,ST^I:7-)0- M<5L+8:JCH9T$T[%6\/*\MXVU [Y Y$#2^Z4=,(Y::B_P8F+L/HANONC+D4%-2^F.,3-BD?"CWR/4-HV3$#80=3)=,CT=#8/NTFX^^/R>$'39X[5P'O!+?+^=G_ODC9)YVGXAD:]]@+GS.E>\P5C5K3O1[/ MS(>4V53P1:F@B7B\,(*LPII(R^,BP$+/YTZ?N5 N<7#94B*TA/PJ-@THDG(T M'2ON/_;7I$I/VR]R5/.L%]DRL_(> $9!L5H\>UUWLD0_)A=MR!8;]JA^[,\? MRLP =>:ES"%#>J=-=N2A:Z%_+%/2Z^??'>^^V[4H.LBXL]@+V):?W *6%)P8O )C<%#[WE%M/XW[SY?;;P_?D!"(*7F%_/G56H_9 M1)I1^)J+$GMUA$7X%FF*J/4/.#;<2HA7?'#! <+H]R M 9/8/YGQITZ 273"_?^-^=B./\99 "8/Z?N:4&!(75,TL^N;@]1:X'VF+SH#.U#ACUCZ@BQ59L8)")U!-D/O M7<+@P.%^W+C#,R*5B.YM;H,J'DBL16IM1#ES< +EWI$^8R&B=WC)18D1660C M]-\C#,G^QKWL_PV14%C0317E=\"-$-_&&=+__!4F,'I*)B.YJABPBVZ$ U;2 MD 7_(XI-8\F$:MT%NSC&V$#0!LRXM^O:\35DYE Z/"J>[$MTC@[\LPA M1]ZZ=T1G?X0'.BY1P8L=<"-WM^VX0^,1&43MN &69#G#!K@,%,>A$+D MZ!6.0A"ZUA84D@8]<)@;7S%%U,:LG?L< G>N-6P756O-K61!K1TFQ#&Q]%8) M4V:)8)'>>60#-+<0!G5WF C'Y 8Z!('HD 5X_1O>% F_ VV \C;&H/0.$^"8 MW:T@"R0V8^*7#S*[V :(;Z4,JN\PZXWIW:/U,-"!D"F)5]J6FP 4:8 71 ,,@5B##](3+$\.PP&\X::<-9L0T. ML^4$71302MX(_D7A#4YD+.R6:8X6- M..B'\W0Z[2_Q-*+*V1 CFZ-_EC"HN_-T.B%WRZ5"]$^R+)NYVO#-\6"?-NB$ MP^PZZ1GFM@NTM"L'J;7>^TQ!B1VFT.8ZU!<8P=T[BZBWP+M$07T=YL,WW#P= MFG-6>/]Y%U5KG:UD0:U=IK5F@Z$$AXKMU[56-\\2DO4XVS.JR?I-$*4YF77M M(4ON.@%/$:W06LL-,P:E=YB:CCDEOE:)S3[I6 1!U*[[/J[6H@-T0<4=9J&W M IN^@'4B$"V\,SN6Q6@ZA49N&%]K!TIH@TXX3$=W* ZE#+$XU(^]4DURQ4X> M],9A:CK&?J@'SDVW-[DW6_*!46D'56OMK61!K1VFHY_YO4#FG4+CS6+"*;R= MR *LM>(07U!TAYEGCIE=[ARDUD+O,P4E=IAYIB?$-F MV&)Z*3/B/63F[75B$3&[UA_L-EBAM38 9@Q*[W*K;A@0A8.8Y#5AB/DZZ=L& M!MQ-*"M5;T.JD >]0,!W'R4?3$ RA2:U?*F8.6.'\2 M^Y73D"DDHJ6^ CA'K- &6&!C#$KO_*%KLJQ]>S6+7W-:Y("]1 .,*" .^N'\ M8>R0*2R0K\@3_H@42C@7^6$OT0 _"HB#?CA?\!R=M ,=TXP7KTG( 1N@_CY? M4'3GZYS'"T3IAU 2\X+,(M%SP :(OL\7%-WY2N:K!18S/2S^*OA*S9/-QD7B M6PLTP 28-VB&\Q7+5^OG%R'$.RX+G=A#-\$&.VG(@_-7V-;;]WVSE"6>*[ M"< %&%]K'TIH@TXX3*=':HY%=L86T3,!%2TR*2M5:U]<9Y.9U]-47BI MSN!JK3] %U3<>;9\&TXH\:\I1X5Y00;6 +UWV8)R.\^0/R#V*,*E\C>W@OL8 MFP=,3S5D(B5"MAEJ;=W @H'^9;/]]9R=&S>!1?Y<<-S_,GT;2 M1_X"4$L#!!0 ( ,]#-%2(/6?2.PP N4 5 :G5P=RTR,#(Q,3(R M.%]L86(N>&ULS9WO<]NV&B L MBVGZ9C ^/!H@DD9T$:>K-X./L^'I[.SR+_ MO/[#<(@N8I(L3M [&@TOTR7]$5WC-3E!OY"4,)Q3]B/ZA).MV$(OXH0P=$;7 MFX3DA.\H#GR"OC\IO0!/U)V MGQU&=-VOP%F.\VU6E7:T.RK_*<)?)W%Z?R+^-<<90?Q\I=G)+HO?#,1QR\,^ M'A]2MAI-CH[&HW^\OYI%=V2-AW$JSEM$!BI*E&*+&[]Z]6HD]RJIH=S-6:*. M<3Q2=JJ2^=ZX15]SDL4GF;1W12.+_ADHV%)N&X\GP>'RXRQ8# M=?+E&60T(1_($LEJGN1/&XY2%@L2!N6V.T:6=C,)8R,1/TK)"N=D(0[T2AQH M_%=QH._*S5=X3I(!$DK.!UBO5XVRRJ"1:[,WA,5T<9Z^S+4>[>15N:8Z3%YFO1SJW?4U>=L;W<>[/-._GR>9H M#_'79%Z57YQJ;@&H2$/&2$:W+"+/:NEZ;?J>U=+A.N$18MI&TN''V> G*4-T MB:00?1'2?[\>[8OV2!2? JYI*HV])^LY84"=+3J7!($VZ^08HF"(@9P9I$B= MXJ20_F92_K/=/,KF'T\F/\C&_]O'F\]?/V/&<)IGYSBZ.]\1%L49GB?D@K)I M2F9WF)'ILN;[-/_A\/LC/EF0NZRL?+MB7:#UK4^"(/%;E>D=W&]<$9US5?(! M(KQL1/:%HR5EB%_=HDP4(CK-QM\$SM$?Q5'0AE^^2DD@_6@U)MR*6G0-'*7( MRQC<,&@=>*7".X*MMG2@*A'Z(F6A#*^5+S[]))?\9^=,K2;T@H=AU(I(I0H/ M$]U:"RI"BJ3VV_*2D>AP11]&"Q)+5/[[%_%S6/R4?/#__?J.1EO)-2]5JY2Y MVP4+D"E!@+[/>[L#AO365A(D-!X:^90??"$,7"1X9:F"MM]5,UMMJ79N[ RB MH6V.]):N-$B(?#;U.Y)%+-Z(6[IM=6G(G#>\Q:31_C5-6!B8QF ::EJ/G?P' MLHJSG,G[_-4(U-*E 7K7PT"K;7U/0W#DJ >A*LHC2Z=INL7)![*A MK VAILPU.3:3.C!U35"<6(R!>!1:5(@]4O'W+68Y8O,F,J@J 'M@=S("%2&A(7.^8.8M?.I4\\*U_0^ 3)L MMS%4B8/%2'?8DR09AD2<1YIJKZET<&0H71,$6-79T61!46/W!O)2R)'4AP'* M>;KHA4FE\P.)9M..2"D*$)"FLRX\N-HW'!=Q%N&D\'/!M^F/8SJTKB$![>J@ M&,*@8('<@< 4 8H;&>(=FG\2S/HA4U/Z <:P:L>ED@4(B^ZM"Q6A]P;*V9:Q MAG-X](&EKE#I,JM8@71!P-)ASGBOJI W8/$X&IVG>9P_B348UUO+>U1VB2L^ M('.*"WU_$#P IG0."AD2.E0(O;6^>JJ0YF+Q"U@E7>:6 KO))@E-34 T6(T! M1.RU"_%<'*9+LCN5_($ULW0N>4"L-D$0Q,%1(;=&8!&*492C;C< M&QPW+%YC]C2+HXYAPQ2ZQ0,RVN1#5P4$"& -(*14H]GEF>]1Y1;O+A<:!^(!&#IFE(X$R>4=V)?W F?<&9 M! W.Y"7@W#[2@, Y?D9UC_V#<]P7G..@P3E^$3B\\;WW.6?\YY3=TD?;"]^@ MT@LVIE4K-'M9>,@8WKJ $0%B?B-"?*,B)UM3=L/H0YQ&\#0:DGN!!C!M)4?3 MAH>/W6 70]4D6<7Y!JFU12:\$!I&NOL9 JU;RQN:);C MY%_QIO4BW2[V@HC5L!64AC(\7&SVNJ I8A /\G7176(K'H!8EZMI^YT]I;;9 MJAY-UW<& 8+-D9G@#AAA$!(^&-(1<$!PZ@6@8H0)&/\HW.995O"G@60)<031J!Y "9#'R)2D,E.L(I WWS-2+3E MX^73>#*_C7,C-9Y=XFQ\ LQ5HY.V/P@^ %,Z#W*?2* XGOQI_F>DHCP@<$UO M&18?,I@]K>[S/4P8#.I#P5U31 8M!@S M+E9**5):7XL=]D/8JGM2L/(V*5AU3 I6(4X*5GTG!2NODP)UZ")-">^CIO,D M7F$@:6*KVC48+99U1BS2H'"!_8%]1Q6"]C$^LFW*M&OB\U%L+3U<\!^6F@(Z M9_DVVVQ6"3=MHB X:7-FI-PL$N'5Q$BH?;"Q7<0Y612&+N(4IU&,DRIUH^WN M>7>(,V)ZFJ_@Z="'P5$_DP9219C*L5@%[M-P^KCM7KS$\9DDR:\I?4QG!& .(@D.KC$'C]1@0-[T444F'EW3)O-'VBR3;- M,9-KV)FMAP)T;ND!;#:IT40!T6)W!E!2B5&A]K44V\BN]D@I6$Y(Z7 MB+>:UE:*6[4!<=-J$%HW7N8)!2I+3> M>#A?$[;BP]TOC#[F=V4.6;!^@-HM'ZV6FYQ8I0'QTN8/X$:%H")&I?WU!]!N MGP"]R )U]8B=8P.:%;CQM"%! UDSB F(9&X'W--,H/R.H//R4\KU MS/5%.3Z_DA)%8L%%,5M/%YC9,&H3._]B"FC8^&Z*H0P"IDY[\#=4J@BD0CR0 M,^4LL_HUGC0BO@\(KJ3H#G%%45_SBJ4N?1!$]32I,E!^Z]%W5J5Z M0GYXVM<0.9XM6PQJD^6:(@A.0%O05+G^?0-_^?RV\R2.+A**X;LP#8WC+'ZF M/2V!WUX0$ 6F*RAMGQ0BJ?3&P%N;AB-"!%O:V55S]5UCZYGM%MN MGE6E)E&]0@-B[3E^ 0KW1:!:&0>UTMV7[[(1D\?;I UD2)M8T MW))=_I8?[+[ERJ-'K.NKNM[5T2_R.@.# /&Y;J%+P S5"T!S\9Y9603Z(@I! MLA0?WVE7SVX:[T 1=D56.)FR(G,X=[IHS>/>-]SUT[7G5$I_VM8G-@A(7V 8 M?!I7E7& BE*0+$9DAMH7!+U77=]TQ7_QS6H3_]<<9X1O^1]02P,$% @ MST,T5%!KMAYN" +&8 !4 !J=7!W+3(P,C$Q,C(X7W!R92YX;6S57=]W MVC88?=\Y^Q\\^DSXD79KLV8[*0T]K&G)0MIN>^D1M@ M0F*2'."_GV0,!6S) M'UMW/J\/J6.NI._>*PM]MN2\_'DUY]$C59I)<=GHG+4;$16Q3)B87C8^C)I7 MH]Y@T(BT(2(A7 IZV1"R\?-/WWX3V7\OOVLVHSZC/+F(7LNX.1 3^6/TGLSI M1?2&"JJ(D>K'Z"/AJ3LC^XQ3%?7D?,&IH?:#3<,7T;.S3H=$S2:@WH]4)%)] MN!OLZIT9L] 7K=9RN3P3\I$LI7K09[&GTDU;77;[4[KMWS_90%\'N1:':AL_!N9$Q,9GME,Y$7 MX7YK;F%-=ZK9Z3;/.V>"ZLRW MEL.T>M+V2QMP5GJFZ.2R8;%+VTBWT^EVG[LFGAR S'IA^Z=FKGLUHM9!\PM% M-14F8WQC3QP4H2MC>Q5-MA6Y]D\,T##CRN1=IQ,U73]+Y[9)>[A!YO%L(^(R M/@B".S_D$>-MW\Y4US0^F\K'5D)9RZGPUU-WV-P<9G+87S]GC5V-M5$D-MO: M.!E3GK7QV6*.(*U_'=F$Z''6*5+=G!*RR,)K46[T]DP69;/=R?O&D_ST9W?U M42?3/1D[UPKAYL!CW'',^_Y>JT?GXR]?O"5V%*%5;NP&A/_(!W]O.C; 1W.OI_PC&XI3IU\^ MW'[Z_(DH1831UR2>7:^HBIEVEVU?JJ&@HYGE-ISLQ71EGI\]:]]2E7WD-<)5 M_55J!OIVCN?;5Z/Z=6S^!_/%[3SUWM9:/ET\1 ]^:\L\4]=MI84(D:3]LK& MD+@X^IQ,R[4]@@#%[:"J6TH+4][75,>*+9Q(%2H?(+&_%4X3NX0DXFAQ1Z?, MI3XNG!V/\/#A*8(]QI\TH 1I(]IQ)41*^!U=2%7APB$2*/[36HA?1A)1\U]3 MH@Q5? V1O0 &*O^L%LI[J&+.5NR,2S,G%D3](AHH__>UD-]'%E'_T8QR[N[D M$P'J_V5XH <_U,(#/^&:N'#]Z"8)EA'U\Z+ FU$.VQ.QV1BJ2B M$04PT((7M;# 0Q5=_&N10*7?0<%)5XV4/^*)J'N?Z9CP351]>Z[LYO5>^"5P MJ/ZX66\E7W0/?J=$@1W8 T/UQTV$*[@BJ-]+E3H(*#CX^-%0_7%3X"JV" 9< M"\/,VJTJ>9]Z;D5;6!$%%1PW[?6Q0Q-Z>_-#&+=R)B3V,1(J.&ZV&V*))GK/ M!JT('XB$KM[2=4CU A0J.VZ6&^2)IONM8G.BUB,65X\M12Q4>=S<-LP43?I[ MLAHD-G0V89LE:M4.>(M C$_0 ,VAJR2QVNG\/\>F$_*E% Y^&E8#-P)\:^1!]S0/NG /<#/A2KXU M\N#\- _.X1[@9L.5?+$]Z-G#H;J72\\C>2\8JC]N-ES!%5O]C,-0W2KYR#;K M_JLL*)2 ^E"')#G,&MN,?*8 N0ZV2*CX=4B8RUEBBWXKM2'\#[:HFJ26XZ$& MU"%U#C'&N"VZZ0CN/HIO/=81!"HV;K9YHL3?L0\14'5Q4^ R5@CB MWDCW<&"+J/)&*N'=EC-;SL>3^73ZE M0*CQE&M]!(&JC)M;EO)"'#JN5_&,B"GU+_0H1T+5QLTU0RQ1 MQ^LI:+R>GCA>X^:PV3FF>Q].U!N0<>*%1]Y*VR(9X8NJ<),S39A-5G@HC8YG([*IZ;!=6EH&X@ M[Z4%LD=[=O&)H%;S1_/@H>6HE4]DJ M7.6Y.CQ0J/YU>'[JX8FWZ'6SUGSWG;5Y1U](?E\)J MU>) :9HVX_,]0]XXS M]DA?$T/R*$-F^$I S:C#0]4P:]3-#JIG64QE>$7!$1 J?1T6))=R1%-\-">< MOTHU5QZ4/?&R679I;O\PTI[RD =: .ZXN# MG/&<6'UY][\MY[TT0P>_F QQ4_#JDQF4, M\3;%I6/.XCZ7)#C_/X!!Q:Y#'ES"#TWK5T0\J'1AXO6MDC&E[OF0WEV+@"P, M6 '4GSIDR"=I@G?WXLN[/K-7?.IA:K*_H&!C#-[#"):#^E2'Y!FB .*<2G_9 MS4>35^L[.J'*+>2XIROSRC;V$)YB 8I#S:K'NZW >B#>@SIX@D+5#9T2/E2; MS?HVVJ3JE030&J#.U2%M/TV5$O->M@H<;:L/]M/\$_?#_6D/>^9O4$L! A0# M% @ ST,T5*SA/L^Y%@ IFT H ( ! &5X.3DM M,2YH=&U02P$"% ,4 " #/0S14K_>16^T5 IH0 "P M@ 'A%@ 9F]R;3@M:RYH=&U02P$"% ,4 " #/0S14WULB9-H# !(#@ M$0 @ 'W+ :G5P=RTR,#(Q,3(R."YX&UL4$L! A0#% @ ST,T5(@]9]([# "Y0 !4 M ( !7SH &IU<';@@ "QF 5 "